W. Frank Peacock IV
High-sensitivity troponin T measurements identified patients with suspected ACS who were at low risk for acute MI and 30-day adverse cardiac events, according to a study published in JAMA Cardiology.
W. Frank Peacock
FACEP, associate chief of emergency medicine research and professor of emergency medicine at Baylor College of Medicine in Houston, and colleagues analyzed data from 1,679 patients (median age, 55 years; 48% women) who presented to 15 EDs with suspected ACS from 2011 to 2015. Patients were excluded for criteria such as an acute MI within the past 3 months, surgery including PCI or hospitalization within the past 3 months and recent defibrillation or cardioversion.
High sensitivity troponin T measurements
Blood samples were collected after patients presented with symptoms at the ED, 3 hours, 6 to 9 hours and 12 to 24 hours later. Follow-up was conducted through telephone contact and medical record review for 30 days for acute cardiac events.
The reference range for the high-sensitivity troponin T assay was determined by evaluating blood samples of 1,301 healthy volunteers (median age, 48 years; 50% women) who did not have a history of chronic disease or a current cancer diagnosis. The 99th percentile high-sensitivity troponin T concentration was 19 ng/L, which was then used as an upper reference level to evaluate diagnostic performance.
Patients with a single high-sensitivity troponin T level of less than 6 ng/L had a negative predictive value of 99.4% for acute MI (95% CI, 98.6-99.8).
Those with serial high-sensitivity troponin T measurements that was less than the upper reference level (77.1%) had a negative predictive value of 99.3% for 30-day adverse cardiac events (95% CI, 99.1-99.6).
Minimal differences were seen in the C-statistic for acute MI between men (0.962) and women (0.952).
“Identifying a low-risk cohort may permit early ED discharge and avoid unnecessary hospitalization,” Peacock and colleagues wrote. “Rapid turnaround of low-risk patients could translate into a reduction in ED volumes, which would benefit patients (shorter waiting times, increased satisfaction, improved outcomes and saved costs), clinicians (decreased diagnostic ambiguity and medicolegal burden) and hospitals (by providing cost-saving benefits).”
“The long-awaited FDA approval of [single high-sensitivity troponin] assays is now here,” Frederick K. Korley, MD, PhD, assistant professor of emergency medicine at University of Michigan Medical School in Ann Arbor, wrote in a related editorial. “There are numerous potential benefits to clinical use of [single high-sensitivity troponin] tests. However, we need to proceed cautiously. To reap the potential rewards of clinical use of [single high-sensitivity troponin] assays, we need (1) a better understanding of the safety of accelerated rule-out strategies in early presenters; (2) a game plan for managing patients without ACS who have elevated high-sensitivity troponin test results; (3) guidelines for distinguishing between type 1 and type 1 non-ST elevation MI and new recommendations for how they ought to be treated; and (4) additional evidence on the optimal cutoff level to rule MI in or out.” – by Darlene Dobkowski
Peacock reports he received grants from Alere and Roche and personal fees from Abbott, Alere, Beckman, Prevencio and Roche. Korley reports he has consulted for Abbott Laboratories and Roche Diagnostics. Please see the study for all other authors’ relevant financial disclosures.